Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Form 144 for NTRA reports a planned insider sale of common stock. The filing covers 36,573 common shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $8,589,169.05. The filing notes that 138,014,465 shares of this class were outstanding.
The shares to be sold were recently acquired from the issuer via equity awards: 35,650 shares from performance stock units on 01/14/2026 and 923 shares from restricted stock units on 01/20/2026. The notice also lists prior sales over the past three months by or for Michael Brophy, including multiple common stock transactions, some under a "10b5-1 Sales Plan," with individual trades ranging from 495 to 1,867 shares and gross proceeds such as $355,924.69 and $236,838.37.
Natera, Inc.’s chief financial officer, Brophy Michael Burkes, reported the vesting of performance-based equity. On January 14, 2026, 59,596 shares of Natera common stock were acquired at a price of $0 per share upon the certification of a performance milestone under a restricted stock unit (RSU) award originally granted on January 27, 2023. The RSUs vest in tranches based on a mix of time-based service and business performance criteria. Following this vesting event, Burkes directly beneficially owns 123,722 shares of Natera common stock.
Natera, Inc. reported an insider equity award for its CEO and President, Steven Leonard Chapman. On January 14, 2026, 152,718 shares of Natera common stock were acquired at a price of $0 per share through the vesting of a performance-based Restricted Stock Unit (RSU) award. This award was originally granted on January 27, 2023 and vests in tranches when a mix of time-based and business performance milestones are achieved.
Following this vesting event, Chapman directly beneficially owned 289,286 shares of Natera common stock. The transaction reflects equity compensation tied to meeting a certified performance threshold rather than an open-market purchase.
Natera, Inc. reported an insider equity award event for John Fesko, its President and Chief Business Officer. On January 14, 2026, he acquired 44,698 shares of Natera common stock at $0 per share, reported as an acquisition of non-derivative securities. This came from a performance-based restricted stock unit (RSU) award granted on January 27, 2023, which vests in tranches when time-based and business performance milestones are achieved. The certification of one such performance milestone triggered this vesting. Following this transaction, Fesko beneficially owns 195,397 shares of Natera common stock directly.
Natera, Inc. executive Solomon Moshkevich reported an equity award tied to performance goals. On January 14, 2026, 44,698 shares of Natera common stock were acquired at $0 per share when a performance threshold under a previously granted performance-based restricted stock unit (RSU) award was certified.
The RSU grant, originally awarded on January 27, 2023, vests in tranches upon achieving milestones based on time and business performance criteria. Following this vesting event, Moshkevich directly beneficially owns 168,197 shares of Natera common stock.
Natera, Inc.’s Secretary and Chief Legal Officer, Daniel Rabinowitz, reported the vesting of 37,248 shares of Common Stock on January 14, 2026. These shares came from a performance-based Restricted Stock Unit award granted on January 27, 2023, which vests in tranches when time and business performance milestones are achieved.
After this zero-cost acquisition, Rabinowitz beneficially owns 245,849 shares of Natera Common Stock directly. The vesting followed certification that a specified performance threshold under the RSUs had been met.
Natera, Inc. director and co-founder Sheena Jonathan reported the vesting of 7,450 shares of Common Stock on January 14, 2026. These shares vested under a performance-based Restricted Stock Unit award granted on January 27, 2023, after a milestone tied to time and business performance criteria was certified. Following this vesting, she holds 270,031 shares of Common Stock directly. She also has indirect beneficial ownership of 22,532 shares held by Caraluna 1 Trust and 22,532 shares held by Caraluna 2 Trust.
Natera, Inc. furnished a current report stating that on January 11, 2026, it issued a press release with preliminary financial results for its fourth quarter and full fiscal year ended December 31, 2025. The press release is included as Exhibit 99.1, giving investors an early look at the company’s recent performance ahead of full audited results. The company specifies that this information, including Exhibit 99.1, is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws or automatically incorporated into other SEC filings unless expressly referenced.
A Natera, Inc. director and co‑founder reported recent changes in their holdings of the company’s common stock. On December 15, 2025, they donated 1,060 shares as a charitable contribution at a reported price of $0.
On December 17, 2025, they sold 1,592, 1,348 and 130 shares in separate transactions at weighted average prices of $226.5404, $227.4355 and $228.2831 per share, effected under a Rule 10b5‑1 trading plan adopted on December 11, 2024. After these transactions, the reporting person directly beneficially owned 222,966 shares, with an additional 23,282 shares held in each of two Caraluna trusts for beneficiaries, over which they disclaim beneficial ownership.
An officer of Natera, Inc. who serves as President, Clinical Diagnostics reported multiple equity transactions in December 2025. On 12/12/2025, the officer made a charitable gift of 180 common shares, exercised 8,876 and 13,500 stock options at an exercise price of $9.59 per share, and sold 4,692 shares at an average price of $230.7575 to cover the option exercise price and tax obligations. On 12/15/2025, the officer made an additional charitable gift of 115 shares. After these transactions, the officer directly owns 126,450 common shares and holds 5,125 stock options at $9.59 per share, which are fully exercisable and expire on 04/07/2026.